Life Science Partner congratulates Max Wallace on his recognition with the CED Life Science Leadership Award for his contributions to the life sciences industry in North Carolina and more broadly.
Mr. Wallace currently serves as CEO of Accelerate Brain Cancer Cure (ABC²), a venture philanthropy organization that has helped bring 30 new brain cancer treatments into the clinic. Life Science Partner recruited him to this post several years ago because of his deep experience bringing impactful treatments to patients. He previously was CEO of TheraLogics, an anti-cancer company based on technology from the University of North Carolina. He also co-founded and served as President of Trimeris, a public company that developed Fuzeon, the first FDA-approved viral entry inhibitor, establishing a whole new class of drugs for HIV/AIDS and other viral diseases.